Vivo Partners with Amdocs to Elevate Their Evolutionary Journey and Achieve Operational Excellence Introduction In an exciting development for the telecommunications industry, Vivo has recently announced a strategic partnership with Amdocs. This collaboration is set to support Vivo’s microservices strategy and systems evolution, ultimately enabling the Brazilian operator to develop and introduce new services quickly…

Assertio Holdings, Inc. Q3 2024 Earnings Conference Call Highlights Company Updates During the Q3 2024 Earnings Conference Call held on November 11, 2024, Assertio Holdings, Inc. (NASDAQ:ASRT) provided key updates on their financial performance and strategic initiatives. CEO Brendan O’Grady and CFO Ajay Patel shared insights into the company’s progress and future outlook. Financial Performance…

Greenbrook Shareholders Give Green Light to Exciting Partnership with Neuronetics TORONTO, Nov. 11, 2024 /PRNewswire/ – Greenbrook TMS Inc. (OTC: GBNHF) (“Greenbrook” or the “Company”) is pleased to announce the voting results from its special meeting of shareholders held on November 8, 2024 The Meeting Greenbrook shareholders have given their overwhelming approval for the proposed…

Therma Bright Inc. Announces Debt Settlements Overview Toronto, Ontario–(Newsfile Corp. – November 11, 2024) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma Bright” or the “Company”), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, announces that the Company has negotiated debt settlements with arm’s length…

Welcome to the World of Intrepid Potash Inc. Intrepid Potash Inc. Investor Presentation Intrepid Potash Inc. (“Intrepid” or “the Company”) (NYSE:IPI) has recently released a new investor presentation, which is now available on the Investor Relations section of the Company’s website at intrepidpotash.com. This presentation provides valuable insights into the world of Intrepid Potash Inc….

Iovance Biotherapeutics Q3 Earnings Review Introduction Iovance Biotherapeutics recently announced their Q3 earnings, which outperformed expectations with $58.6 million in revenue. Despite this positive news, the company’s shares fell due to high market expectations and concerns about competition in the industry. Overview of Amtagvi Amtagvi, Iovance’s lead drug, has shown strong commercial potential. The company…